All you need to get started with ETF selection and analysis. Create your account now →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
PBE ETF · Invesco Dynamic Biotechnology & Genome ETF
The PBE Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Biotech & Genome Intellidex Index. The PBE ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.+15.08%
Last price
$79.82
1M perf.
+4.57%
1M flows
+€1.4M
AuM
€215M
E/R
0.58%
Rating
ESG Consensus®
PBE
$79.82
Performance & flows
Segment for quartile rank
January 23, 2026 → April 23, 2026
Create a free account to view the flows graph
PBE
$80.07
-3.23%
BioTech & Genomics
-4.18%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +4.57%  | -3.23%  | +34.33%  | +28.62% | +5.99% | +1.04% | +1.04% | -2.37% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
4/23/2026
$80.07
1D NAV change
-1.35%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
30
Inception date
6/23/2005
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Fund
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Benchmark
Dynamic Biotech & Genome Intellidex Index
Asset class
Factors
N/A
Investment strategy
The Invesco Dynamic Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidexâ„ Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
FXH
1M perf.
+7.08%
E/R
0.61%
FHH
1M perf.
+5.85%
E/R
0.76%
SLTY
1M perf.
-4.21%
E/R
1.24%
XHE
1M perf.
+3.47%
E/R
0.35%
00678
1M perf.
+4.87%
E/R
1.01%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -3.23% | +34.33% | +28.62% | +5.99% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
92.18%
United Kingdom
3.05%
Netherlands
2.41%
Cayman Islands
2.36%
Sectors
Health Care
97.59%
Unavailable
2.41%
Diversification
Total weight of top 15 holdings out of 30
Top 15 holdings
Data as of March 31, 2026
UTD THERAPEUT
ILLUMINA
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
BIOGEN INC
AMGEN-T
GILEAD SCIENCES
INCYTE
Create a free account to view top holdings
BIOCRYST PHARMACEUTICALS
PROTAGONIST THERAPEUTICS INC
TG THERAPEUTICS
ROYALTY PHARMA
NEUROCRINE BIOSCIENCES
CATALYST PHARMACEUTICALS INC
PTC THERAPEUTI/D
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
ESG Consensus® by Conser
Data as of February 27, 2026
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about PBE ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
PBE’s has a Final Sustainability Grade of either B+, B, or B-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
81.30% of holdings have positive scoring
18.70% of holdings have negative scoring
10.20%
62.28%
8.82%
10.31%
8.39%
Consensus levels
Strong
Medium
Weak
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
1-year trailing difference
As of March 31, 2026
Create a free account to view the replication graph
PBE
N/A
Replication quality
Calculated over 12m, as of March 31, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
Invesco
Invesco ID Card
Number of funds
633
Total AuM
€904.1B
Expense ratio range
0.04% - 5.39%
Average expense ratio
0.3558%
Top 5 funds by Invesco
| AuM | ||
|---|---|---|
QQQ | Invesco QQQ ETF | €365.5B |
RSP | Invesco S&P 500® Equal Weight ETF | €74.76B |
QQQM | Invesco NASDAQ 100 ETF | €68.87B |
SPXS | Invesco S&P 500 UCITS ETF | €32.06B |
SGLD | Invesco Physical Gold USD ETC | €25.99B |
Frequently asked questions about PBE
What does Invesco Dynamic Biotechnology & Genome ETF, PBE, invest in?
PBE is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
Which benchmark or index does PBE replicate?
PBE tracks the Dynamic Biotech & Genome Intellidex TR Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of PBE?
PBE carries a total expense ratio (TER) of 0.58%, indicating the annual cost for holding the fund.
When was PBE launched?
PBE was introduced to the market on June 23, 2005. It trades on United States
Who is the ETF issuer of PBE?
Invesco Dynamic Biotechnology & Genome ETF, PBE, is provided by Invesco. Learn more about Invesco here.
What is the current assets under management (AUM) of PBE?
PBE oversees €215M in assets as of April 23, 2026.
How has PBE performed lately?
Based on data from April 23, 2026, PBE returned 4.57% over the past month, -3.23% over the last three months and -2.37% year-to-date.
What are the latest inflows or outflows for PBE?
As of April 23, 2026, PBE recorded net flows of +€1.4M over the last month and -€1.8M year-to-date.
Does PBE distribute dividends?
PBE follows a distributing dividend policy, meaning it pays out income to investors. As of April 23, 2026, its 12-month trailing yield was 1.08%.
What are the main country or region exposures of PBE?
As of March 31, 2026, PBE has significant geographic allocations in USA, United Kingdom and Netherlands.
In which sector or theme does PBE invest in?
As of March 31, 2026, PBE focuses largely on Health Care.
How many securities does PBE hold and how diversified is it?
As of March 31, 2026, PBE holds 30 positions in its portfolio, with 63.66% of assets concentrated in its top 15 holdings.
What are the main positions in PBE?
As of March 31, 2026, PBE top three holdings include UTD THERAPEUT, ILLUMINA and REGENERON PHARMACEUTICALS.
What is the base currency of PBE?
The base currency of PBE is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
